Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

LGND

Ligand Pharmaceuticals, Inc.

Apr 18 • 04:00PM ET

72.52

Dollar change -6.35
Percentage change -8.05	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IJR VTI IWM VB VBR VXF IJS PJP IWN IBB

Index	RUT	P/E	25.00	EPS (ttm)	2.90	Insider Own	6.22%	Shs Outstand	17.56M	Perf Week	-10.94%
Market Cap	1.28B	Forward P/E	12.94	EPS next Y	5.60	Insider Trans	-0.18%	Shs Float	16.60M	Perf Month	0.43%
Income	52.15M	PEG	1.25	EPS next Q	0.89	Inst Own	92.15%	Short Float	4.05%	Perf Quarter	1.81%
Sales	131.31M	P/S	9.78	EPS this Y	-26.85%	Inst Trans	-0.32%	Short Ratio	4.01	Perf Half Y	29.13%
Book/sh	39.92	P/B	1.82	EPS next Y	25.78%	ROA	6.94%	Short Interest	0.67M	Perf Year	-4.84%
Cash/sh	9.62	P/C	7.54	EPS next 5Y	20.00%	ROE	8.29%	52W Range	49.24 - 94.57	Perf YTD	1.54%
Dividend Est.	-	P/FCF	28.47	EPS past 5Y	-13.18%	ROI	7.38%	52W High	-23.32%	Beta	1.00
Dividend TTM	-	Quick Ratio	12.72	Sales past 5Y	-3.89%	Gross Margin	67.06%	52W Low	47.28%	ATR (14)	2.76
Dividend Ex-Date	Jul 02, 2010	Current Ratio	14.15	EPS Y/Y TTM	253.69%	Oper. Margin	7.48%	RSI (14)	40.45	Volatility	3.70% 3.14%
Employees	58	Debt/Eq	0.01	Sales Y/Y TTM	-40.20%	Profit Margin	39.72%	Recom	1.20	Target Price	116.80
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	199.40%	Payout	0.00%	Rel Volume	0.78	Prev Close	78.87
Sales Surprise	9.58%	EPS Surprise	108.87%	Sales Q/Q	-44.22%	Earnings	Feb 27 BMO	Avg Volume	167.55K	Price	72.52
SMA20	-4.58%	SMA50	-3.67%	SMA200	8.38%	Trades		Volume	131,218	Change	-8.05%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300
Aug-17-18	Initiated	Goldman	Neutral	$256
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy	$260
Dec-27-17	Reiterated	H.C. Wainwright	Buy	$163 → $169
Sep-05-17	Resumed	H.C. Wainwright	Buy	$150
Oct-05-16	Reiterated	H.C. Wainwright	Buy	$146 → $160
Aug-05-16	Downgrade	Deutsche Bank	Hold → Sell	$104 → $110

Show Previous Ratings

Apr-17-24 09:55AM	Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know (Zacks)
Apr-08-24 08:15AM	Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference (Business Wire)
Apr-05-24 06:00PM	Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts (Zacks)
Apr-04-24 09:30AM	Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It? (Zacks)
09:00AM	Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know (Zacks)
09:00AM	Loading…
Apr-03-24 09:00AM	Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI (Business Wire)
Apr-01-24 06:15PM	Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note (Zacks)
Mar-28-24 11:30AM	Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-26-24 06:15PM	Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Mar-21-24 09:00AM	Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock (Zacks)
Mar-20-24 06:00PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Mar-19-24 09:30AM	Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-14-24 06:00PM	Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors (Zacks)
Mar-07-24 09:00AM	Is Trending Stock Ligand Pharmaceuticals Incorporated (LGND) a Buy Now? (Zacks)
Mar-05-24 04:01PM	Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference (Business Wire)
08:00AM	Loading…
Mar-04-24 08:00AM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-29-24 09:30AM	Wall Street Analysts See Ligand (LGND) as a Buy: Should You Invest? (Zacks) -5.93%
Feb-28-24 07:34AM	Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges (Zacks) -5.44%
Feb-27-24 07:00AM	Ligand Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire) +19.86%
Feb-22-24 04:01PM	Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa (Business Wire)
Feb-16-24 08:00AM	Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires (Business Wire)
Feb-13-24 04:01PM	Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Business Wire) -6.13%
Feb-01-24 05:00PM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-10-24 07:30PM	Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene (GlobeNewswire)
Jan-05-24 04:30PM	U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum (Business Wire)
Dec-12-23 12:01PM	Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance (Business Wire)
09:00AM	Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life (GlobeNewswire)
09:00AM	Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations (GlobeNewswire)
Dec-11-23 09:00AM	Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology (GlobeNewswire)
Dec-06-23 04:02PM	Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City (Business Wire)
08:20AM	Loading…
Dec-01-23 08:20AM	Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications (GlobeNewswire)
Nov-28-23 09:01AM	Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-09-23 04:47PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:01PM	Ligand Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-06-23 09:00AM	Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial (GlobeNewswire)
Nov-01-23 08:00AM	Ligand Acquires Royalty on Sanofis TZIELD for $20 Million (Business Wire)
Oct-25-23 04:01PM	Ligand To Report Third Quarter 2023 Financial Results On November 8 (Business Wire)
Oct-18-23 08:00AM	Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026 (GlobeNewswire)
Oct-09-23 06:15PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Oct-03-23 06:00PM	Ligand Pharmaceuticals (LGND) Stock Moves -0.71%: What You Should Know (Zacks)
Oct-02-23 09:00AM	Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer (GlobeNewswire)
09:00AM	Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms (GlobeNewswire)
Sep-27-23 09:00AM	Ligand Acquires Assets of Novan, Inc. for $12.2 Million (Business Wire)
Sep-26-23 05:05PM	Ligand Appoints Martine Zimmermann to its Board of Directors (Business Wire)
Sep-22-23 09:00AM	Ligands Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (Business Wire)
Sep-21-23 09:20AM	Ligands Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control (Business Wire)
Sep-18-23 05:17PM	Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio (Business Wire)
Sep-01-23 10:02PM	Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Aug-08-23 04:01PM	Ligand Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-27-23 01:30PM	Ligands Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials (Business Wire)
Jul-25-23 04:30PM	Ligand To Report Second Quarter 2023 Financial Results On August 8 (Business Wire)
Jul-17-23 08:59AM	Ligand Offers $15 Million to Acquire Assets of Novan, Inc. (Business Wire)
08:45AM	Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection (GlobeNewswire)
Jun-29-23 09:00AM	Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting (GlobeNewswire)
Jun-21-23 08:00PM	LGND: Lowering target price to $81.00 (Argus Research)
Jun-09-23 09:40AM	Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-06-23 11:40AM	LGND or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
11:10AM	UnitedHealth (UNH) Intends to Buy Amedisys to Boost Home-Health (Zacks)
Jun-05-23 11:49AM	Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat (Zacks) -5.72%
09:01AM	Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer (GlobeNewswire)
Jun-02-23 12:39PM	FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer (Zacks) +5.77%
12:35PM	Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study (Zacks)
Jun-01-23 11:29AM	Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates (Zacks)
May-30-23 07:01PM	3 Stocks That Smart Investors Should Be Flocking to Now (InvestorPlace)
May-25-23 05:00PM	Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023 (GlobeNewswire)
May-24-23 09:55AM	Wall Street Analysts Think Ligand (LGND) Could Surge 44.42%: Read This Before Placing a Bet (Zacks)
09:40AM	Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year? (Zacks)
May-17-23 01:59PM	Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study (Zacks)
08:07AM	Zacks.com featured highlights include J.B. Hunt Transport Services, Archer-Daniels-Midland, NVIDIA, Tractor Supply and AmerisourceBergen (Zacks)
May-16-23 09:56AM	Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far (Zacks)
07:30AM	Ligands Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) (Business Wire)
07:00AM	Load Up on These 5 Exceptional Relative Price Strength Stocks (Zacks)
May-12-23 12:08PM	ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why (Zacks)
11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
May-11-23 12:25PM	Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View (Zacks)
May-08-23 12:32PM	Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings (Zacks)
09:55AM	Wall Street Analysts Believe Ligand (LGND) Could Rally 38.66%: Here's is How to Trade (Zacks)
May-06-23 10:13AM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ? (Simply Wall St.)
May-05-23 10:00AM	Best Momentum Stocks to Buy for May 5th (Zacks)
May-04-23 05:45PM	Ligand Pharmaceuticals (LGND) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
04:01PM	Ligand Reports First Quarter 2023 Financial Results (Business Wire)
06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
May-02-23 08:30PM	2 Medical Stocks to Buy Before Earnings (Zacks)
12:06PM	Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/Y (Zacks)
11:40AM	LGND vs. REGN: Which Stock Is the Better Value Option? (Zacks)
Apr-28-23 02:04PM	Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y (Zacks)
Apr-27-23 09:04AM	Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates (Zacks)
Apr-26-23 08:00PM	LGND: Lowering target price to $81.00 (Argus Research)
Apr-24-23 04:01PM	Ligand to Report First Quarter 2023 Financial Results on May 4, 2023 (Business Wire)
Apr-20-23 09:55AM	Does Ligand (LGND) Have the Potential to Rally 41.24% as Wall Street Analysts Expect? (Zacks)
Apr-19-23 08:30AM	Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today (Zacks)
Apr-18-23 12:56PM	Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data (Zacks)
Apr-17-23 01:13PM	Bristol Myers (BMY), TSVT Application for Abecma Accepted (Zacks)
09:40AM	Is Hologic (HOLX) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-14-23 01:48PM	Merck's (MRK) Keytruda sBLA Accepted by FDA for Gastric Cancer (Zacks)
Apr-13-23 06:28AM	Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 41%? (Simply Wall St.)
Apr-07-23 06:40PM	Tillys, American Public Education Stock See Action From Activist Investors (Barrons.com)
Apr-06-23 10:23AM	Here's Why You Should Add Ligand (LGND) Stock to Your Portfolio (Zacks)
Apr-04-23 12:02PM	Oncternal (ONCT) Down on Restructuring Plan to Extend Runway (Zacks)
09:55AM	Wall Street Analysts Predict a 53.67% Upside in Ligand (LGND): Here's What You Should Know (Zacks)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Davis Todd C	Chief Executive Officer	Mar 25 '24	Option Exercise	57.39	16,015	919,147	120,160	Mar 27 05:47 PM
Aryeh Jason	Director	Mar 05 '24	Option Exercise	39.35	2,893	113,840	74,422	Mar 06 05:28 PM
Sabba Stephen L	Director	Mar 05 '24	Option Exercise	0.00	2,893	0	30,819	Mar 07 01:27 PM
Sabba Stephen L	Director	Mar 05 '24	Sale	74.30	1,893	140,650	28,926	Mar 07 01:27 PM
Espinoza Octavio	Chief Financial Officer	Feb 28 '24	Option Exercise	56.62	1,264	71,564	29,895	Feb 29 06:50 PM
Espinoza Octavio	Chief Financial Officer	Feb 28 '24	Sale	88.46	140	12,384	29,755	Feb 29 06:50 PM
Davis Todd C	CHIEF EXECUTIVE OFFICER	Sep 22 '23	Buy	59.38	4,000	237,529	73,090	Sep 25 04:44 PM
KOZARICH JOHN W	Director	May 16 '23	Sale	77.20	4,444	343,081	38,488	May 18 05:18 PM
Sabba Stephen L	Director	May 10 '23	Option Exercise	0.00	6,408	0	32,192	May 12 03:43 PM
Sabba Stephen L	Director	May 10 '23	Sale	77.13	6,408	494,225	25,784	May 12 03:43 PM
KOZARICH JOHN W	Director	May 08 '23	Option Exercise	18.82	6,408	120,599	48,621	May 10 07:15 PM
KOZARICH JOHN W	Director	May 08 '23	Sale	76.56	6,408	490,628	42,213	May 10 07:15 PM

Open in Screener

MACK

Merrimack Pharmaceuticals Inc

Apr 18 • 04:00PM ET

14.68

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

MACK Merrimack Pharmaceuticals Inc daily Stock Chart

Held by: VTI DWAS IWM VXF IWO DFAT VTWO IWC DFAS VFMV

Index	RUT	P/E	-	EPS (ttm)	-0.08	Insider Own	1.21%	Shs Outstand	14.53M	Perf Week	-0.34%
Market Cap	213.30M	Forward P/E	-	EPS next Y	-	Insider Trans	127.90%	Shs Float	14.36M	Perf Month	-0.07%
Income	-1.18M	PEG	-	EPS next Q	-	Inst Own	64.11%	Short Float	5.03%	Perf Quarter	11.63%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-0.55%	Short Ratio	5.78	Perf Half Y	19.54%
Book/sh	1.31	P/B	11.24	EPS next Y	-	ROA	-6.05%	Short Interest	0.72M	Perf Year	16.42%
Cash/sh	1.30	P/C	11.30	EPS next 5Y	5.60%	ROE	-6.22%	52W Range	11.53 - 15.89	Perf YTD	9.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	56.22%	ROI	-6.30%	52W High	-7.61%	Beta	1.44
Dividend TTM	-	Quick Ratio	43.50	Sales past 5Y	0.00%	Gross Margin	-	52W Low	27.32%	ATR (14)	0.08
Dividend Ex-Date	Dec 13, 2019	Current Ratio	43.50	EPS Y/Y TTM	27.67%	Oper. Margin	0.00%	RSI (14)	52.74	Volatility	0.30% 0.46%
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	4.00	Target Price	4.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	53.22%	Payout	-	Rel Volume	0.91	Prev Close	14.68
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Mar 07 AMC	Avg Volume	125.14K	Price	14.68
SMA20	-0.25%	SMA50	0.56%	SMA200	12.61%	Trades		Volume	113,575	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-16	Downgrade	JP Morgan	Overweight → Neutral
May-27-16	Initiated	Robert W. Baird	Neutral	$8
Dec-23-15	Reiterated	Mizuho	Buy	$16 → $13
Oct-27-15	Reiterated	Oppenheimer	Outperform	$13 → $15
Apr-21-15	Reiterated	Mizuho	Buy	$13 → $16
Oct-10-14	Resumed	Oppenheimer	Outperform	$9 → $11
Jul-08-14	Resumed	Brean Capital	Buy	$16
Jun-20-14	Reiterated	Oppenheimer	Outperform	$10 → $8.50
Aug-09-13	Reiterated	Oppenheimer	Outperform	$12 → $10
Jun-25-13	Initiated	Mizuho	Buy	$12
May-08-12	Initiated	Oppenheimer	Outperform	$12

Show Previous Ratings

Mar-27-24 04:30PM	Merrimack Receives $225 Million Milestone Payment from Ipsen (Business Wire)
Mar-08-24 08:51AM	MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023 (InvestorPlace)
Mar-07-24 04:30PM	Merrimack Reports Full Year 2023 Financial Results (Business Wire)
Feb-13-24 04:18PM	Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (Business Wire) +7.22%
Dec-29-23 01:48PM	Hedge Fund and Insider Trading News: Chase Coleman, Bill Ackman, Jonathan Hoenig, Bridgewater Associates, Merrimack Pharmaceuticals Inc (MACK), HighPeak Energy, Inc. (HPK), and More (Insider Monkey)
04:30PM	Loading…
Nov-02-23 04:30PM	Merrimack Reports Third Quarter 2023 Financial Results (Business Wire)
Aug-15-23 07:02AM	Western Standard LLC Boosts Stake in Merrimack Pharmaceuticals Inc (GuruFocus.com)
Aug-03-23 04:30PM	Merrimack Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-03-23 08:24AM	Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Can Afford To Invest In Growth (Simply Wall St.)
May-04-23 05:00PM	Merrimack Reports First Quarter 2023 Financial Results (Business Wire)
Apr-19-23 07:02AM	Retail investors account for 38% of Merrimack Pharmaceuticals, Inc.'s (NASDAQ:MACK) ownership, while hedge funds account for 33% (Simply Wall St.)
Mar-09-23 04:40PM	Merrimack Reports Full Year 2022 Financial Results (Business Wire)
Jan-23-23 08:44AM	Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its Business (Simply Wall St.)
Dec-28-22 10:15PM	12 Best Performing Biotech Stocks in 2022 (Insider Monkey)
Dec-13-22 06:44AM	Bullish Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insiders filled their treasuries with US$574k worth of stock over last year (Simply Wall St.)
09:00AM	Loading…
Dec-05-22 09:00AM	Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan (Business Wire)
Nov-17-22 06:56AM	The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen (Zacks)
Nov-16-22 11:28AM	Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More (Zacks)
Nov-10-22 05:11AM	Hedge funds investors control 44% of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) and were rewarded last week after stock increased 228% (Simply Wall St.)
Nov-09-22 10:13AM	Merrimack stock rockets 200% after positive trial data on Onivyde pancreatic cancer treatment (MarketWatch) +212.75%
09:04AM	Why Merrimack Shares Are Surging Over 200% Today? (Benzinga)
Nov-03-22 04:45PM	Merrimack Reports Third Quarter 2022 Financial Results (Business Wire)
Aug-16-22 08:11AM	Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth (Simply Wall St.)
Aug-04-22 05:00PM	Merrimack Reports Second Quarter 2022 Financial Results (Business Wire)
Aug-03-22 11:49AM	Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure (Benzinga) -14.46%
08:30AM	Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer (Business Wire)
Jul-06-22 07:07AM	Bullish insiders at Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) loaded up on US$574k of stock earlier this year (Simply Wall St.)
May-05-22 04:30PM	Merrimack Reports First Quarter 2022 Financial Results (Business Wire)
Mar-09-22 04:30PM	Merrimack Reports Full Year 2021 Financial Results (Business Wire) +5.49%
Jan-27-22 04:48AM	Insider Buying: The Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Co-Founder & Independent Director Just Bought 63% More Shares (Simply Wall St.) -5.34%
07:22AM	Loading…
Dec-06-21 07:22AM	Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation (Simply Wall St.)
Nov-04-21 05:00PM	Merrimack Reports Third Quarter 2021 Financial Results (Business Wire)
Sep-06-21 09:50AM	A Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insider increased their holdings by 43% last year (Simply Wall St.)
Aug-05-21 04:30PM	Merrimack Reports Second Quarter 2021 Financial Results (Business Wire)
Jun-08-21 05:31AM	Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Can Afford To Invest In Growth (Simply Wall St.)
Jun-07-21 02:10PM	Elevation Oncology Files for $100M IPO (Benzinga)
May-28-21 08:00AM	180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors (GlobeNewswire)
Mar-10-21 06:00PM	Merrimack Reports Full Year 2020 Financial Results (Business Wire)
Dec-10-20 02:10AM	How Much Of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Do Institutions Own? (Simply Wall St.)
Dec-03-20 07:46AM	The Daily Biotech Pulse: Lilly Secures Additional Orders For COVID-19 Antibody Treatment, Decision Day For BioCryst, Kinnate Biopharma To Make Wall Street Debut (Benzinga) -6.01%
Nov-29-20 12:12PM	Where Do Hedge Funds Stand On Merrimack Pharmaceuticals Inc (MACK)? (Insider Monkey)
Nov-05-20 08:20AM	Merrimack Reports Third Quarter 2020 Financial Results (Business Wire)
Aug-07-20 08:20AM	Merrimack Reports Second Quarter 2020 Financial Results (Business Wire)
Aug-05-20 08:33AM	We Think Merrimack Pharmaceuticals (NASDAQ:MACK) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-07-20 06:10PM	Merrimack Reports First Quarter 2020 Financial Results (Business Wire)
Apr-02-20 08:30AM	Merrimack Divests Early Stage Asset for $2.25 Million; Provides Strategy Update (Business Wire) +8.60%
Feb-07-20 11:14AM	What Kind Of Share Price Volatility Should You Expect For Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)? (Simply Wall St.)
Dec-22-19 07:44PM	Hedge Funds Are Selling Merrimack Pharmaceuticals Inc (MACK) (Insider Monkey)
Dec-03-19 09:15AM	Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan (Business Wire) +9.87%
08:45AM	Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend (Business Wire)
Oct-28-19 06:04AM	Proxy fights reach 'frightening' level in life sciences, other industries, top attorney says (American City Business Journals)
Sep-24-19 04:45PM	JFL Capital Ends Campaign at Merrimack (PR Newswire)
Sep-19-19 03:23PM	Should You Buy Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) For This Reason? (Simply Wall St.)
09:00AM	Merrimack Pharmaceuticals Announces Changes to Board of Directors (Business Wire)
Aug-26-19 11:27AM	Texas investor group fighting for control of crumbling Merrimack Pharmaceuticals (American City Business Journals)
09:00AM	Merrimack Pharmaceuticals Issues Letter to Shareholders (Business Wire)
Aug-22-19 08:30AM	JFL Capital Issues Letter to Fellow Merrimack Stockholders (PR Newswire)
Aug-16-19 09:15AM	Merrimack Pharmaceuticals Reschedules 2019 Annual Meeting of Shareholders for October 17, 2019 (Business Wire)
Jul-25-19 08:30AM	Merrimack Declares $20 Million Special Dividend (PR Newswire) +7.59%
May-31-19 07:34AM	The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering (Benzinga) -6.09%
06:21AM	Merrimack axes remaining staff, execs after selling assets to New York startup (American City Business Journals)
May-30-19 04:05PM	Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend (PR Newswire)
May-10-19 07:30AM	Merrimack Reports First Quarter 2019 Financial Results (PR Newswire)
May-06-19 01:46PM	COMM 2014-UBS2 Mortgage Trust -- Moody's affirms ten classes of COMM 2014-UBS2 (Moody's)
May-03-19 05:43PM	COMM 2014-UBS2 Mortgage Trust -- Moody's affirms ten classes of COMM 2014-UBS2 (Moody's)
Apr-18-19 03:07PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK (GlobeNewswire)
Apr-16-19 04:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK (ACCESSWIRE)
Apr-12-19 01:57PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK (GlobeNewswire)
Apr-09-19 05:50PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK (PR Newswire)
Apr-08-19 10:12AM	Merrimack Pharmaceuticals, Inc. (MACK) - Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation (ACCESSWIRE)
Apr-05-19 08:29AM	The Merrimack Pharmaceuticals (NASDAQ:MACK) Share Price Is Down 92% So Some Shareholders Are Rather Upset (Simply Wall St.) -16.41%
07:48AM	The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership (Benzinga)
Apr-04-19 05:58PM	Merrimack shelves another cancer drug, plans more layoffs (American City Business Journals)
04:15PM	Merrimack Discontinues Development of MM-310 (PR Newswire)
Mar-07-19 09:06AM	Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4 (Zacks)
Mar-06-19 07:00AM	Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results (PR Newswire) +8.63%
Feb-12-19 07:35AM	New Research: Key Drivers of Growth for ON Semiconductor, Entegris, Universal, MarineMax, Epizyme, and Merrimack Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production (GlobeNewswire)
Feb-11-19 09:39AM	Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely? (Zacks)
Jan-28-19 10:19PM	Edited Transcript of MACK earnings conference call or presentation 7-Nov-18 1:30pm GMT (Thomson Reuters StreetEvents)
Dec-10-18 05:00PM	John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman (GlobeNewswire)
Nov-09-18 10:31AM	Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3 (Zacks)
08:45AM	Research Report Identifies Merrimack Pharmaceuticals, PNM Resources, Inc. (Holding Co.), Carrols Restaurant Group, American Axle & Manufacturing, CBIZ, and Nova Measuring Instruments with Renewed Outlook Fundamental Analysis, Calculating Forward Movement (GlobeNewswire)
Nov-08-18 10:17AM	Merrimack to shelve lead cancer drug, lay off most of workforce (American City Business Journals)
Nov-07-18 06:45AM	Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review (PR Newswire) +9.20%
Nov-06-18 01:44PM	Merrimack Pharmaceuticals Q3 Earnings Preview (Benzinga)
Nov-05-18 07:55AM	5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings (Zacks)
Oct-31-18 04:05PM	Merrimack Announces Timing of Third Quarter 2018 Investor Conference Call (PR Newswire)
Oct-24-18 11:19AM	Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod (Zacks) -6.67%
Oct-19-18 10:48AM	Merrimack's String of Failures Continues With Lung Cancer Study Shelved After Midstage Trials (Benzinga) -22.29%
07:46AM	Merrimack Pharmaceuticals' stock plummets toward record low after cancer drug trial terminated (MarketWatch)
06:00AM	Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility (PR Newswire)
Oct-16-18 07:30AM	Detailed Research: Economic Perspectives on Clearside Biomedical, JELD-WEN Holding, L.B. Foster, Merrimack Pharmaceuticals, Everi, and Drive Shack What Drives Growth in Today's Competitive Landscape (GlobeNewswire)
Oct-11-18 05:16PM	Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts (Zacks)
Sep-20-18 07:00AM	Merrimack Receives $5 Million Milestone Payment from Shire (PR Newswire)
Sep-06-18 10:35AM	Merrimack (MACK) Up 6.7% Since Last Earnings Report: Can It Continue? (Zacks) -5.75%
06:50AM	Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC) (PR Newswire)
Sep-05-18 12:06PM	Edited Transcript of MACK earnings conference call or presentation 7-Aug-18 12:30pm GMT (Thomson Reuters StreetEvents)
Sep-04-18 10:07AM	Zacks.com highlights: American Woodmark, Adverum Biotechnologies, Merrimack Pharmaceuticals, Athene Holding and M&T Bank (Zacks)
Aug-16-18 08:00AM	Factors of Influence in 2018, Key Indicators and Opportunity within Celsion, Alpha and Omega Semiconductor, SP Plus, Merrimack Pharmaceuticals, La Jolla Pharmaceutical, and SPX New Research Emphasizes Economic Growth (GlobeNewswire)
Aug-08-18 10:20AM	Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2 (Zacks)

Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Andersen Eric	Director	Dec 28 '23	Buy	13.35	857	11,441	534,008	Dec 28 04:05 PM
Andersen Eric	Director	Dec 26 '23	Buy	13.15	48,693	640,313	533,151	Dec 28 04:05 PM
Andersen Eric	Director	Dec 07 '23	Buy	12.85	101,050	1,298,472	1,735,600	Dec 11 04:05 PM
Andersen Eric	Director	Nov 17 '23	Buy	12.50	300	3,750	1,659,216	Nov 20 06:59 PM
Andersen Eric	Director	Nov 14 '23	Buy	12.50	50,170	627,125	1,658,981	Nov 16 05:09 PM
Andersen Eric	Director	Nov 09 '23	Buy	12.19	9,975	121,618	1,577,704	Nov 13 04:05 PM
Andersen Eric	Director	Nov 08 '23	Buy	12.13	13,823	167,701	1,569,894	Nov 13 04:05 PM
CROCKER GARY L	See Remarks	Aug 11 '23	Buy	12.43	2,000	24,865	133,105	Aug 14 04:06 PM
CROCKER GARY L	See Remarks	Aug 10 '23	Buy	12.52	2,000	25,039	133,105	Aug 14 04:06 PM
Andersen Eric	Director	Aug 08 '23	Buy	12.00	87,057	1,044,327	1,565,111	Aug 09 04:06 PM
Andersen Eric	Director	Aug 07 '23	Buy	12.00	134,493	1,614,414	1,496,680	Aug 09 04:06 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

LGND

Ligand Pharmaceuticals, Inc.

MACK

Merrimack Pharmaceuticals Inc

Upgrade your FINVIZ experience